Spots Global Cancer Trial Database for CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)
Official Title: Significance of CYP19 Genetic Polymorphism on Musculoskeletal Symptom & Complication of Aromatase Inhibitor(AI)
Study ID: NCT00973505
Interventions
Study Description
Brief Summary: The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Korea University Anam Hopital, Seoul, , Korea, Republic of
Contact Details
Name: Eun Sook Lee, MD, PhD
Affiliation: Korea University Anam Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
